Consumer electronics producer Samsung and insurance firm Axa have exited UK-based digital wellness app developer BioBeats in an acquisition of undisclosed size by health technology and services provider Huma.
Huma announced the deal alongside its purchase of Tarilian Laser Technologies, a producer of non-invasive blood pressure monitors, and its rebranding from Medopad.
Founded in 2012 as a spinout of University of Surrey, Biobeats has built a personal wellness app called BioBase that can be paired with wearable devices to monitor mental health-related biometric and psychometric markers such as heart rate.
The company had raised a total of $6.3m, most recently closing a $3.1m round in 2018 co-led by university venture fund Oxford Sciences Innovation, White Cloud Capital and IQ Capital.
White Cloud Capital had previously led a $2.3m round for Biobeats in 2016, investing with IQ Capital and Axa subsidiary Axa Venture Partners.
The company’s investors also included Samsung Next, a corporate venturing vehicle for Samsung, as well as record label Cantora, Italian Angels for Growth, Eniac Ventures, ZhenFund, Luminous Ventures and Zynik Capital.